Management of patients exposed to biological and chemical warfare agents

Journal of Intensive Care Medicine

Volumn 17, Issue 4, 2002, Pages 147-161

  Marik, Paul E ^a   Bowles, Stephen ^b  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b MERCY HOSPITAL OF PITTSBURGH   (United States)

Author keywords

Anthrax; Bioterrorism; Chemical warfare agents; Smallpox

Indexed keywords

BOTULINUM TOXIN; CHEMICAL WARFARE AGENT; MUSTARD GAS;

ANTHRAX; ANXIETY; BIOLOGICAL WARFARE; CHEMICAL WARFARE; FEAR; HEALTH CARE SYSTEM; HUMAN; LAW; PANIC; PLAGUE; PRIORITY JOURNAL; REVIEW; SMALLPOX; TERRORISM; TULAREMIA;

EID: 33645173126     PISSN: 08850666     EISSN: 15251489     Source Type: Journal    
DOI: 10.1177/0885066602017004001     Document Type: Review

References (104)

1. Global proliferation of weapons of mass destruction. Hearings before the Permanent Subcommittee on Investigations of the Committee on Governmental Affairs, US Senate, 104th Cong, 1st sess, part 1, October 31, 1995.
2. US Congress, Office of Technology Assessment. Proliferation of weapons of mass destruction: assessing the risks. Washington, DC: Office of Technology Assessment, 1993. Document OTA ISC 559.
3. US Congress, Office of Technology Assessment. Technologies underlying weapons of mass destruction. Washington, DC: Office of Technology Assessment, 1993. Document OTA ISC 115.
4. Fee E, Brown TM. Preemptive biopreparedness: can we learn anything from history? Am J Public Health 2001;91:721-726.
5. Khan AS, Morse S, Lillibridge S. Public-health preparedness for biological terrorism in the USA. Lancet 2000;356:1179-1182.
6. Haines JD, Pitts K, Crutcher JM. Medical response to bioterrorism: are we prepared? J Okla State Med Assoc 2000;93:187-196.
7. Henderson DA. The looming threat of bioterrorism. Science 1999;283:1279-1282.
8. Henderson DA. Weapons for the future. Lancet 1999;354(suppl):SIV64
9. Wetter DC, Daniell WE, Treser CD. Hospital preparedness for victims of chemical or biological terrorism. Am J Public Health 2001;91:710-716.
10. Woodall J. Tokyo subway gas attack. Lancet 1997;350:296.
11. Derbes VJ. Mussis and the great plague of 1348: a forgotten episode of bacteriological war. JAMA 1966;196:5962.
12. Christopher GW, Cieslak TJ, Palvin JA, et al. Biological warfare: a historical perspective. JAMA 1997;278:412.
13. Stearn EW, Stearn AE. The effect of smallpox on the density of the Amerindian. Boston, MA: Bruce Humphries, 1945.
14. Harris S. Japanese biological warfare research on humans: a case study of microbiology and ethics. Ann N Y Acad Sci 1992;666:21-52.
15. Meselson M, Guillemin J, Hugh-Jones M. The Sverdlovsk anthrax outbreak of 1979. Science 1994;266:1202-1208.
16. Zilinskas RA. Iraq's biological weapons: the past as future? JAMA 1997;278:418-424.
17. Orient JM. Chemical and biological warfare: should defenses be researched and deployed? JAMA 1989;262:644-648.
18. US Congress, Office of Technology Assessment. Proliferation of weapons of mass destruction: assessing the risks. Washington, DC: Office of Technology Assessment, 1993. Document OTA ISC 559.
19. Torok TJ, Tauxe RV, Wise RP. A large community outbreak of salmonellosis caused by intentional contamination of restaurant salad bars. JAMA 1997;278:389-395.
20. Centers for Disease Control Prevention. Biological and chemical terrorism: strategic plan for preparedness and response-recommendations of the CDC strategic planning workgroup. Morb Mort Wkly Rep 2000;49:1-14.
21. Arita I. Virological evidence for the success of the smallpox eradication program. Nature 1979;279:293-298.
22. Alibek K, Aria I. The confirmation and maintenance of smallpox eradication. N Engl J Med 1980;303:1263-1273.
23. Ferrer F, Henderson DA, Arita I, et al. Smallpox and its eradication. Geneva: World Health Organization, 1988.
24. Henderson DA, Inglesby TV, Bartlett JG. Smallpox as a biological weapon: medical and public health management. JAMA 1999;281:2127-2137.
25. Ellner PD. Smallpox: gone but not forgotten. Infection 1998;26:263-269.
26. Mopp SL, Knight JC, Massung RF, et al. PCR strategy for identification and differentiation of smallpox and other orthopoxviruses. J Clin Microbiol 1995;33:2069-2076.
27. Franz DR, Jahrling PB, Friedlander AM. Clinical recognition and management of patients exposed to biological warfare agents. JAMA 1997;278:399-411.
28. Lew DP. Bacillus anthracis (anthrax). In: Mandell GL, Bennet JE, Dolin R, eds. Principles and practice of infectious disease. Philadelphia: Churchill Livingstone, 2000:2215-2220.
29. Swartz MN. Current concepts: recognition and management of anthrax-an update. N Engl J Med 2001;345:1621-1626.
30. Myenye KS, Siziya S, Peterson D. Factors associated with human anthrax outbreak in the Chikupo and Ngandu villages of Murewa district in Mashonaland East Province, Zimbabwe. Cent Afr J Med 1996;42:312-315.
31. Watson A, Keir D. Information on which to base assessments of risk from environments contaminated with anthrax spores. Epidemiol Infect 1994;113:479-490.
32. Taylor JP, Dimmitt DC, Ezzell JW, et al. Indigenous human cutaneous anthrax in Texas. South Med J 1993;86:1-4.
33. Brachman PS. Anthrax. Ann N Y Acad Sci 1970;174:577-582.
34. Brachman PS. Inhalational anthrax. Ann N Y Acad Sci 1980;363:830-89.
35. Brachman PS, Kaufman AF, Dalldorf FGF. Industrial inhalation anthrax. Bacteriol Rev 1966;30:659.
36. Albrink WS. Pathogenesis of inhalation anthrax. Bacteriol Rev 1991;25:268-273.
37. Penn CC, Klotz SA. Anthrax pneumonia. Sem Respir Infect 1997;12:28-30.
38. Lincoln RE, Hodges DR, Klein F. Role of the lymphatics in the pathogenesis of anthrax. J Infect Dis 1965;115:481-494.
39. Vessal K, Yeganehdoust J, Dutz W, et al. Radiologic changes in inhalation anthrax. Clin Radiol 1975;26:471-474.
40. Amramova FA, Grinberg LM, Yampolskaya O, et al. Pathology of inhalational anthrax in 42 cases from the Sverdlovsk outbreak in 1979. Proc Natl Acad Sci U S A 1993;90:2291-2294.
41. Inglesby TV, Henderson DA, Hartlett JG. Anthrax as a biological weapon: medical and public health management. JAMA 1999;281:1735-1745.
42. Harrison LH, Ezzell JW, Abshire TG. Evaluation of serological tests for the diagnosis of anthrax after an outbreak of cutaneous anthrax in Paraguay. J Infect Dis 1989;39:578-581.
43. Turnbull PC, Doganay M, Lindeque PM. Serology and anthrax in humans, livestock, and Etosha National Park wildlife. Epidemiol Infect 1992;108:299-313.
44. Black JD, Dolly JO. Interaction of 1251-labeled botulism neurotoxins with nerve terminals: II: autoradiologic evidence of its uptake into motor neurons by receptor mediated endocytosis. J Cell Biol 1986;103:535-544.
45. Herrero BA, Ecklung AE, Street CS, et al. Experimental botulism in monkeys: a clinical pathological study. Exp Mol Pathol 1967;6:84-95.
46. Scott AB, Suzuki D. Systemic toxicity of botulinum toxin by intramuscular injection in the monkey. Movement Disord 1988;3:333-335.
47. Shapiro RL, Hatheway C, Swerdlow DL. Botulism in the United States: a clinical and epidemiologic review. Ann Intern Med 1998;129:221-228.
48. United Nations Security Council. Tenth report of the executive chairman of the special commission established by the secretary-general pursuant to paragraph 9(b)(1) of Security Council Resolution 687 (1991), and paragraph 3 of Resolution 699 (1991) on the Activities of the Special Commission. S/1995/1038. New York: United Nations Security Council, 1995.
49. Gordesman AH. Weapons of mass destruction in the Gulf and greater Middle East: force trends, strategy, tactics and damage effects. 18-52. Washington, DC: Center for Strategic and International Studies, 1998.
50. Burrows WD, Renner SE. Biological warfare agents as threats to potable water. Environ Health Perspect 1999;107:975-984.
51. Hughes JM, Blumenthal JK, Merson MU, et al. Clinical features of types A and B food-borne botulism. Ann Intern Med 1981;95:442-445.
52. Edell TA, Sullivan CP Jr, Osborn KM, et al. Wound botulism associated with a positive tensilon test. West J Med 1983;139:218-219.
53. Notermans S, Nagel J. Assays for botulism and tetanus toxins. In: Simpson LL, ed. Botulism neurotoxin and tetanus toxin. San Diego, CA: Academic Press, 1989:319-331.
54. Cherington M. Clinical spectrum of botulism. Muscle Nerve 1998;21:701-710.
55. Arnon S, Schecter R, Inglesby TV. Botulism toxin as a biological weapon: medical and public health management. JAMA 2001;285:1059-1070.
56. Black RE, Gunn RA. Hypersensitivity reactions associated with botulinal antitoxin. Am J Med 1980;69:567-570.
57. Tacket CO, Shandera WX, Mann JM, et al. Equine antitoxin use and other factors that predict outcome in type A foodborne botulism. Am J Med 1984;76:794-798.
58. Schulze J, Toepfer M, Schroff KC, et al. Clindamycin and nicotinic neuromuscular transmission. Lancet 1999;354:1792-1793.
59. Hopla CE. The ecology of tularemia. Adv Vet Sci Comp Med 1974;18:25-53.
60. Evans ME, Gregory DW, Schaffner W, et al. Tularemia: a 30-year experience with 88 cases. Medicine 1985;64:251-269.
61. Christenson B. An outbreak of tularemia in the northern part of central Sweden. Scand J Infect Dis 1984;16:285-290.
62. Warring WB, Ruffin JS. A tick-borne epidemic of tularemia. N Engl J Med 1946;234:137-140.
63. Markowitz LE, Hynes NA, de la Cruz CP, et al. Tick-borne tularemia: an outbreak of lymphadenopathy in children. JAMA 1985;254:2922-2925.
64. Young LS, Bickness DS, Archer BG, et al. Tularemia epidemia: Vermont, 1968: forty-seven cases linked to contact with muskrats. N Engl J Med 1969;280:1253-1260.
65. Mignani E, Palmieri F, Fontana M, et al. Italian epidemic of waterborne tularaemia. Lancet 1988;2:1423.
66. Teutsch SM, Martone WJ, Brink EW, et al. Pneumonic tularemia on Martha's Vineyard. N Engl J Med 1979;301:826-828.
67. Syrjala H, Kujala P, Myllyla V, et al. Airborne transmission of tularemia in farmers. Scand J Infect Dis 1985;17:371-375.
68. World Health Organization. Health aspects of chemical and biological weapons. Geneva: World Health Organization, 1970.
69. Cox SK, Everett ED. Tularemia, an analysis of 25 cases. Missouri Med 1981;78:70-74.
70. Ohara Y, Sato T, Fujita H, et al. Clinical manifestations of tularemia in Japan-analysis of 1,355 cases observed between 1924 and 1987. Infection 1991;19:14-17.
71. Avery FW, Barnett TB. Pulmonary tularemia: a report of five cases and consideration of pathogenesis and terminology. Am Rev Respir Dis 1967;95:584-591.
72. Syrjala H, Koskela P, Ripatti T, et al. Agglutination and ELISA methods in the diagnosis of tularemia in different clinical forms and severities of the disease. J Infect Dis 1986;153:142-145.
73. Bevanger L, Maeland JA, Naess AI. Agglutinins and antibodies to Francisella tularensis outer membrane antigens in the early diagnosis of disease during an outbreak of tularemia. J Clin Microbiol 1988;26:433-437.
74. Grunow R, Splettstoesser W, McDonald S, et al. Detection of Francisella tularensis in biological specimens using a capture enzyme-linked immunosorbent assay, an immunochromatographic handheld assay, and a PCR. Clin Diagn Lab Immunol 2000;7:86-90.
75. Higgins JA, Hubalek Z, Halouzka J, et al. Detection of Francisella tularensis in infected mammals and vectors using a probe-based polymerase chain reaction. Am J Trop Med Hyg 2000;62:310-318.
76. Perry RD, Fetherston JD. Yersinia pestis-etiologic agent of plague. Clin Microbiol Rev 1997;10:35-66.
77. Centers for Disease Control and Prevention. Fatal human plague. Morb Mort Wkly Rep 1997;278:380-382.
78. World Health Organization. Health aspects of chemical and biological weapons. Geneva: World Health Organization, 1970.
79. Butler T. Yersina species, including plague. In: Mandell GL, Bennet JE, Dolin R, eds. Principles and practice of infectious diseases. Philadelphia: Churchill Livingstone, 2000:2406-2414.
80. Inglesby TV, Dennis DT, Henderson DA, et al. Plague as a biological weapon: medical and public health management. JAMA 2000;283:2281-2290.
81. Wilmoth BA, Chu MC, Quan TJ. Identification of Yersinia pestis by BBL crystal enteric/nonfermenter identification system. J Clin Microbiol 1996;34:2829-2830.
82. McCormick JH, Webb PA, Krebs JW, et al. A prospective study of the epidemiology and ecology of lassa fever. J Infect Dis 1987;155:437-444.
83. Fulhorst CF, Bowen MD, Ksiazek TG, et al. Isolation and characterization of Whitewater Arroyo virus, a novel North American arenavirus. Virology 1996;224:114-120.
84. Maiztegui J, Feuillade M, Briggiler A. Progressive extension of the endemic area and changing incidence of Argentine hemorrhagic fever. Med Microbiol Immunol 1986;175:149-152.
85. Johnson KM, Wiebenga NH, Mackenzie RH. Virus isolations from human cases of hemorrhagic fever in Bolivia. Proc Soc Exp Biol Med 1965;155:113-118.
86. Stinebaugh BJ, Schloeder FX, Johnson KM, et al. Bolivian hemorrhagic fever: a report of four cases. Am J Med 1966;40:217-230.
87. Salas R, de Manzione N, Tesh RB, et al. Venezuelan haemorrhagic fever. Lancet 1991;338:1033-1036.
88. Lisieux T, Coimbra M, Nassar ES, et al. New arenavirus isolated in Brazil. Lancet 1994;343:391-392.
89. Easterday HC. Rift valley fever. Adv Vet Sci 1965;10:65-127.
90. Enria DA, Briggiler AM, Fernandez NJ, et al. Importance of dose of neutralising antibodies in treatment of Argentine haemorrhagic fever with immune plasma. Lancet 1984;2:255-256.
91. McCormick JB, King IJ, Webb PA, et al. Lassa fever: effective therapy with ribavirin. N Engl J Med 1986;314:20-26.
92. Huggins JW. Prospects for treatment of viral hemorrhagic fevers with ribavirin, a broad-spectrum antiviral drug. Rev Infect Dis 1989;11(suppl 4):S750-S761.
93. Enria DA, Maiztegui JI. Antiviral treatment of Argentine hemorrhagic fever. Antiviral Res 1994;23:23-31.
94. Haley RW, Kurt TI. Self-reported exposure to neurotoxic chemical combinations in the Gulf War: a cross-sectional epidemiologic study. JAMA 1997;277:231-237.
95. Landrigan PJ. Illness in Gulf War veterans. JAMA 1997;277:259-261.
96. Haley RW, Hom J, Roland PS, et al. Evaluation of neurologic function in Gulf War veterans. JAMA 1997;277:223-230.
97. Haley RW, Kurt TL, Hom J. Is there a Gulf War syndrome? Searching for syndromes by factor analysis of symptoms. JAMA 1997;277:215-222.
98. Blewett WK. Tactical weapons: is mustard still king? NBC Defense Technol Int 1986;1:64-66.
99. Medema J. Mustard gas: the science of H. NBC Defense Technol Int 1986;1:66-71.
100. Momeni A, Enshaeih S, Meghdadi M, et al. Skin manifestations of mustard gas: clinical study of 535 patients exposed to mustard gas. Arch Dermatol 1992;128:775-780.
101. Emad A, Rezaian GR. The diversity of the effects of sulphur mustard gas inhalation on respiratory system 10 years after a single, heavy exposure. Chest 1997;112:734-738.
102. Dunn MA, Sidell FR. Progress in medical defense against nerve agents. JAMA 1989;262:649-652.
103. Sidell FR, Horak J. Chemical warfare agents: II: nerve agents. Ann Emerg Med 1992;21:865-871.
104. Gunderson CH, Lehmann CR, Sidell FR, et al. Nerve agents: a review. Neurology 1992;42:946-950.